Saturday, November 11, 2006

Meta-analysis favors glatiramer

Carra A. P635 ECTRIMS 2004. Odds ratio for relapse, disability progression favors glatiramer over interferon groups.

Based on pooled data of four open nonrandomized trials. Patients n= 695 with 135 patients on GA having less relapses and accumulated disability.

No comments: